AU551407B2 - Crystalline human leukocyte interferon - Google Patents

Crystalline human leukocyte interferon

Info

Publication number
AU551407B2
AU551407B2 AU91155/82A AU9115582A AU551407B2 AU 551407 B2 AU551407 B2 AU 551407B2 AU 91155/82 A AU91155/82 A AU 91155/82A AU 9115582 A AU9115582 A AU 9115582A AU 551407 B2 AU551407 B2 AU 551407B2
Authority
AU
Australia
Prior art keywords
human leukocyte
leukocyte interferon
crystalline human
interferon
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU91155/82A
Other versions
AU9115582A (en
Inventor
Hsiang-Fu Kung
David L. Miller
Sidney Pestka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU9115582A publication Critical patent/AU9115582A/en
Application granted granted Critical
Publication of AU551407B2 publication Critical patent/AU551407B2/en
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG Alteration of Name(s) in Register under S187 Assignors: F. HOFFMANN-LA ROCHE AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

(For the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE) 1. Human leukocyte interferon (IFN-alpha in crystalline form. (For the Contracting State AT) 1. A process for the manufacture of human leukocyte interferon in crystalline form, characterized by treating an aqueous solution of the interferon at a concentration of at least about 0.2 mg/ml with polyethylene glycol (PEG).
AU91155/82A 1981-12-07 1982-12-06 Crystalline human leukocyte interferon Ceased AU551407B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32787681A 1981-12-07 1981-12-07
US327876 1981-12-07

Publications (2)

Publication Number Publication Date
AU9115582A AU9115582A (en) 1983-06-16
AU551407B2 true AU551407B2 (en) 1986-05-01

Family

ID=23278463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU91155/82A Ceased AU551407B2 (en) 1981-12-07 1982-12-06 Crystalline human leukocyte interferon

Country Status (12)

Country Link
EP (1) EP0083734B1 (en)
JP (1) JPS58164597A (en)
AT (1) ATE18410T1 (en)
AU (1) AU551407B2 (en)
CA (1) CA1209038A (en)
DE (1) DE3269727D1 (en)
DK (1) DK159164C (en)
IE (1) IE54374B1 (en)
IL (1) IL67411A0 (en)
NZ (1) NZ202698A (en)
PH (1) PH20413A (en)
ZA (1) ZA828917B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441734A (en) * 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
CN1245215C (en) 2001-02-28 2006-03-15 四川省生物工程研究中心 Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA796175B (en) * 1978-11-24 1980-11-26 Hoffmann La Roche Purified proteins and process therefor

Also Published As

Publication number Publication date
ATE18410T1 (en) 1986-03-15
ZA828917B (en) 1983-09-28
AU9115582A (en) 1983-06-16
IE54374B1 (en) 1989-09-13
EP0083734A1 (en) 1983-07-20
IE822882L (en) 1983-06-07
DK159164B (en) 1990-09-10
IL67411A0 (en) 1983-05-15
EP0083734B1 (en) 1986-03-05
JPH0477000B2 (en) 1992-12-07
PH20413A (en) 1987-01-05
CA1209038A (en) 1986-08-05
DK538482A (en) 1983-06-08
DE3269727D1 (en) 1986-04-10
DK159164C (en) 1991-02-11
JPS58164597A (en) 1983-09-29
NZ202698A (en) 1986-02-21

Similar Documents

Publication Publication Date Title
AU562938B2 (en) 7, 10, 13, 16 docosatetraenoic acid composition
ZA907338B (en) Thienylcarboxylates of amino alcohols
GR3006807T3 (en)
DE3462852D1 (en) Medicament preparation for external use comprising adenosin for the treatment of herpes
TW272968B (en)
AU551407B2 (en) Crystalline human leukocyte interferon
EP0407815A3 (en) Polyprenyl compound composition for soft capsules
HUT44126A (en) Herbicide composition containing pyridine-monocarboxylic acid derivative with sulfur-containing group at the 5th position as active component and process for producing the active component
GR77037B (en)
PL151373B2 (en)
EP0215949A4 (en) Process for preparing 16-substituted prostaglandin e's.
EP0410652A3 (en) Improvement of excretion of potassium ion by prostanoic acid derivatives
AU553275B2 (en) Stable oxytetracyclin solutions
USD267550S (en) Combination set protractor
ZA891077B (en) Process for the preparation of 1,2-disulfone compounds
ES8606248A1 (en) Process for the preparation of optically active glycine derivatives.
OA08918A (en) Process for the enrichment of canallite by flotation.
PT79860A (en) Process for the preparation of 2-thiazoline and 2-oxozoline with antidote activity against non-selective herbicides